IDEAS home Printed from https://ideas.repec.org/e/c/pmc184.html
   My authors  Follow this author

Christopher Joseph McCabe

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Wikipedia or ReplicationWiki mentions

(Only mentions on Wikipedia that link back to a page on a RePEc service)
  1. Katherine J. Stevens & Christopher J. McCabe & John E. Brazier, 2006. "Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey," Health Economics, John Wiley & Sons, Ltd., vol. 15(5), pages 527-533, May.

    Mentioned in:

    1. Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey (Health Economics 2006) in ReplicationWiki ()

Working papers

  1. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.

    Cited by:

    1. Refoios Camejo, Rodrigo & McGrath, Clare & Herings, Ron, 2011. "A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness," Health Policy, Elsevier, vol. 100(1), pages 18-24, April.
    2. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    3. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Management of Dementia Patients - A Systematic Literature Review," Working Papers 2018:41, Lund University, Department of Economics.
    4. Mike Paulden & Christopher McCabe & Jonathan Karnon, 2014. "Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?," PharmacoEconomics, Springer, vol. 32(4), pages 315-318, April.
    5. Ryuichi Ohta & Yoshinori Ryu & Daisuke Kataoka & Chiaki Sano, 2021. "Effectiveness and Challenges in Local Self-Governance: Multifunctional Autonomy in Japan," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
    6. Thomas Delea & Paul Tappenden & Oleg Sofrygin & Dominy Browning & Mayur Amonkar & Jon Karnon & Mel Walker & David Cameron, 2012. "Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 589-603, October.
    7. Christopher Wai Hung Yau & Erik Lenguerrand & Steve Morris & Tim Draycott & Elena Pizzo, 2021. "A model-based cost-utility analysis of multi-professional simulation training in obstetric emergencies," PLOS ONE, Public Library of Science, vol. 16(3), pages 1-18, March.
    8. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    9. Scott Metcalfe & Rachel Grocott, 2010. "Comments on “Simoens, S. Health Economic Assessment: A Methodological Primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966”—New Zealand in Fact Has No Cost-Effectiveness Threshold," IJERPH, MDPI, vol. 7(4), pages 1-4, April.
    10. Lionel Perrier & Anne Lefranc & Philippe Quittet & Philippe Moreau & Carole Siani & Hervé Ghesquières & Fabrice Jardin & Bertrand Favier & Norbert Ifrah & Séverine Lissandre & David Pérol & Catherine , 2013. "Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma," Post-Print halshs-00752571, HAL.
    11. Irz, Xavier & Jensen, Jørgen Dejgaard & Leroy, Pascal & Réquillart, Vincent & Soler, Louis-Georges, 2017. "A Cross-Country Comparison of the Sustainability Effects of Dietary Recommendations," 2017 International Congress, August 28-September 1, 2017, Parma, Italy 261114, European Association of Agricultural Economists.
    12. A. Newall & M. Jit & R. Hutubessy, 2014. "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines," PharmacoEconomics, Springer, vol. 32(6), pages 525-531, June.
    13. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
    14. Liran Einav & Amy Finkelstein & Heidi Williams, 2016. "Paying on the Margin for Medical Care: Evidence from Breast Cancer Treatments," American Economic Journal: Economic Policy, American Economic Association, vol. 8(1), pages 52-79, February.
    15. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    16. Mike Paulden & Karl Claxton, 2012. "Budget allocation and the revealed social rate of time preference for health," Health Economics, John Wiley & Sons, Ltd., vol. 21(5), pages 612-618, May.
    17. Sanjib Saha & Ulf-G Gerdtham & Pia Johansson, 2010. "Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular Diseases," IJERPH, MDPI, vol. 7(8), pages 1-46, August.
    18. Khachapon Nimdet & Nathorn Chaiyakunapruk & Kittaya Vichansavakul & Surachat Ngorsuraches, 2015. "A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold?," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-16, April.
    19. Stefano Capri & Rosella Levaggi, 2011. "Shifting the risk in pricing and reimbursement schemes? A model of risk-sharing agreements for innovative drugs," DEP - series of economic working papers 2/2011, University of Genoa, Research Doctorate in Public Economics.
    20. Hossein Haji Ali Afzali & Jonathan Karnon & Mark Sculpher, 2016. "Should the Lambda (λ) Remain Silent?," PharmacoEconomics, Springer, vol. 34(4), pages 323-329, April.
    21. Andrew Willan & Simon Eckermann, 2012. "Value of Information and Pricing New Healthcare Interventions," PharmacoEconomics, Springer, vol. 30(6), pages 447-459, June.
    22. László Gulácsi & Alexandru Rotar & Maciej Niewada & Olga Löblová & Fanni Rencz & Guenka Petrova & Imre Boncz & Niek Klazinga, 2014. "Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 13-25, May.
    23. Fredslund, Eskild Klausen & Mørkbak, Morten Raun & Gyrd-Hansen, Dorte, 2018. "Different domains – Different time preferences?," Social Science & Medicine, Elsevier, vol. 207(C), pages 97-105.
    24. Simon Eckermann & Brita Pekarsky, 2014. "Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room," PharmacoEconomics, Springer, vol. 32(4), pages 319-325, April.
    25. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    26. Martin Hoyle, 2011. "Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 29(1), pages 1-15, January.
    27. Mark Sculpher & Karl Claxton, 2012. "Real Economics Needs to Reflect Real Decisions," PharmacoEconomics, Springer, vol. 30(2), pages 133-136, February.
    28. Mark Sculpher & Karl Claxton, 2010. "Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1132-1136, October.
    29. Nadine Schur & Salvatore Brugaletta & Angel Cequier & Andrés Iñiguez & Antonio Serra & Pilar Jiménez-Quevedo & Vicente Mainar & Gianluca Campo & Maurizio Tespili & Peter den Heijer & Armando Bethencou, 2018. "Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial," PLOS ONE, Public Library of Science, vol. 13(8), pages 1-16, August.
    30. B. Corbacho & M. Drummond & R. Santos & E. Jones & J. M. Borràs & J. Mestre-Ferrandiz & J. Espín & N. Henry & A. Prat, 2020. "Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 621-634, June.
    31. Anna Nicolet & Antoinette D I van Asselt & Karin M Vermeulen & Paul F M Krabbe, 2020. "Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    32. Grupo de Economía de la Salud & Jairo Humberto Restrepo, 2012. "Economía de las enfermedades crónicas no transmisibles: Implicaciones para Colombia," Observatorio Seguridad Social 15579, Grupo de Economía de la Salud.
    33. Tomasz Fundament & Paul R Eldridge & Alexander L Green & Alan L Whone & Rod S Taylor & Adrian C Williams & W M Michael Schuepbach, 2016. "Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-18, July.
    34. Helen Dakin & Nancy Devlin & Yan Feng & Nigel Rice & Phill O'Neill & David Parkin, 2015. "The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1256-1271, October.
    35. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    36. Anne Girault & Chloe Gerves-Pinquie & Serena Phillips & Sarah Raskin & Mandi Pratt-Chapman, 2018. "Economic evaluation of patient navigation programs in colorectal cancer care, a systematic review," Post-Print hal-01973691, HAL.
    37. Antoine Poncet & Baris Gencer & Marc Blondon & Marianne Gex-Fabry & Christophe Combescure & Dipen Shah & Peter J Schwartz & Marie Besson & François R Girardin, 2015. "Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-14, June.
    38. Chloé Gervès-Pinquié & Anne Girault & Serena Phillips & Sarah Raskin & Mandi Pratt-Chapman, 2018. "Economic evaluation of patient navigation programs in colorectal cancer care, a systematic review," Health Economics Review, Springer, vol. 8(1), pages 1-12, December.
    39. Benjamin Cadier & Isabelle Durand-Zaleski & Daniel Thomas & Karine Chevreul, 2016. "Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-17, February.
    40. Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe, 2014. "Some Inconsistencies in NICE’s Consideration of Social Values," PharmacoEconomics, Springer, vol. 32(11), pages 1043-1053, November.
    41. Zanfina Ademi & Kumar Pasupathi & Danny Liew, 2017. "Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 363-374, June.
    42. Carlos K. H. Wong & Brian H. H. Lang & Vivian Y. W. Guo & Cindy L. K. Lam, 2016. "Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 647-657, December.
    43. Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk, 2015. "Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany," PharmacoEconomics, Springer, vol. 33(11), pages 1215-1228, November.
    44. J. Jaime Caro & Erik Nord & Uwe Siebert & Alistair McGuire & Maurice McGregor & David Henry & Gérard de Pouvourville & Vincenzo Atella & Peter Kolominsky‐Rabas, 2010. "The efficiency frontier approach to economic evaluation of health‐care interventions," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1117-1127, October.
    45. Charlotta Pisinger & Cecilie Goltermann Toxværd & Mette Rasmussen, 2022. "Smoking Cessation Programs Are Less Effective in Smokers with Low Socioeconomic Status Even When Financial Incentives for Quitting Smoking Are Offered—A Community-Randomized Smoking Cessation Trial in," IJERPH, MDPI, vol. 19(17), pages 1-15, August.
    46. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
    47. Irz, Xavier & Leroy, Pascal & Réquillart, Vincent & Soler, Louis-Georges, 2016. "Welfare and sustainability effects of dietary recommendations," Ecological Economics, Elsevier, vol. 130(C), pages 139-155.
    48. Klingler, Corinna & Shah, Sara M.B. & Barron, Anthony J.G. & Wright, John S.F., 2013. "Regulatory space and the contextual mediation of common functional pressures: Analyzing the factors that led to the German Efficiency Frontier approach," Health Policy, Elsevier, vol. 109(3), pages 270-280.
    49. Colantone, Italo & Crinò, Rosario & Ogliari, Laura, 2019. "Globalization and mental distress," Journal of International Economics, Elsevier, vol. 119(C), pages 181-207.
    50. Laura Bojke & Laetitia Schmitt & James Lomas & Gerry Richardson & Helen Weatherly, 2018. "Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments," IJERPH, MDPI, vol. 15(11), pages 1-9, November.
    51. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017. "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 469-477, August.
    52. Roland Diel & Niklas Lampenius & Albert Nienhaus, 2015. "Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations," PharmacoEconomics, Springer, vol. 33(8), pages 783-809, August.
    53. Jinsong Geng & Hao Yu & Yiwei Mao & Peng Zhang & Yingyao Chen, 2015. "Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes," PharmacoEconomics, Springer, vol. 33(6), pages 581-597, June.
    54. Yazdan Yazdanpanah & Julian Perelman & Madeline A DiLorenzo & Joana Alves & Henrique Barros & Céu Mateus & João Pereira & Kamal Mansinho & Marion Robine & Ji-Eun Park & Eric L Ross & Elena Losina & Ro, 2013. "Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-1, December.
    55. Alena M Pfeil & Oliver Reich & Ines M Guerra & Sandrine Cure & Francesco Negro & Beat Müllhaupt & Daniel Lavanchy & Matthias Schwenkglenks, 2015. "Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-20, May.
    56. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    57. Laura Levaggi & Rosella Levaggi, 2011. "Welfare properties of restrictions to health care based on cost effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 101-110, January.
    58. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
    59. F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
    60. Eva Kaltenthaler & Christopher Carroll & Daniel Hill-McManus & Alison Scope & Michael Holmes & Stephen Rice & Micah Rose & Paul Tappenden & Nerys Woolacott, 2017. "Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process," PharmacoEconomics - Open, Springer, vol. 1(2), pages 99-108, June.
    61. L. Gulácsi & M. Péntek, 2014. "HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 675-680, September.
    62. Job F. H. Eijsink & Mohamed N. M. T. Al Khayat & Cornelis Boersma & Peter G. J. Horst & Jan C. Wilschut & Maarten J. Postma, 2021. "Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 75-88, February.
    63. Karl Claxton & Mike Paulden & Hugh Gravelle & Werner Brouwer & Anthony J. Culyer, 2011. "Discounting and decision making in the economic evaluation of health‐care technologies," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 2-15, January.
    64. Roberta Longo & Paul Baxter & Peter Hall & Jenny Hewison & Mehran Afshar & Geoff Hall & Christopher McCabe, 2014. "Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin," PharmacoEconomics, Springer, vol. 32(4), pages 327-334, April.
    65. Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe, 2015. "Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework," PharmacoEconomics, Springer, vol. 33(3), pages 255-269, March.
    66. Francesca Pierotti & Ilaria Palla & Maarten Treur & Lara Pippo & Giuseppe Turchetti, 2015. "Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-18, October.
    67. Daniel Howdon & James Lomas, 2017. "Pricing implications of non-marginal budgetary impacts in health technology assessment: a conceptual model," Working Papers 148cherp, Centre for Health Economics, University of York.
    68. Jelle Schoemaker & Simon van Genderen & Willem I. J. de Boer, 2019. "Increased Physical Activity in Preparation for a Women-Only Mass Participation Sport Event: A Framework for Estimating the Health Impact," IJERPH, MDPI, vol. 17(1), pages 1-11, December.
    69. Jamie Elvidge & Ash Bullement & Anthony J. Hatswell, 2016. "Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK," PharmacoEconomics, Springer, vol. 34(11), pages 1145-1159, November.
    70. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
    71. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.

  2. Karl Claxton & Simon Eggington & Laura Ginnelly & Susan Griffin & Christopher McCabe & Zoe Philips & Paul Tappenden & Alan Wailoo, 2005. "A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence," Working Papers 004cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Alan Brennan & Samer Kharroubi & Anthony O'Hagan & Jim Chilcott, 2007. "Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms," Medical Decision Making, , vol. 27(4), pages 448-470, July.
    2. Zoe Philips & Karl Claxton & Stephen Palmer, 2008. "The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions?," Medical Decision Making, , vol. 28(3), pages 287-299, May.
    3. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
    4. Susan Griffin & Nicky J. Welton & Karl Claxton, 2010. "Exploring the Research Decision Space: The Expected Value of Information for Sequential Research Designs," Medical Decision Making, , vol. 30(2), pages 155-162, March.
    5. Felipa de Mello-Sampayo, 2022. "On the timing and probability of Presurgical Teledermatology: how it becomes the dominant strategy," Health Care Management Science, Springer, vol. 25(3), pages 389-405, September.
    6. Josh J. Carlson & Rahber Thariani & Josh Roth & Julie Gralow & N. Lynn Henry & Laura Esmail & Pat Deverka & Scott D. Ramsey & Laurence Baker & David L. Veenstra, 2013. "Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics," Medical Decision Making, , vol. 33(4), pages 463-471, May.
    7. Bas Groot Koerkamp & M. G. Myriam Hunink & Theo Stijnen & Milton C. Weinstein, 2006. "Identifying key parameters in cost‐effectiveness analysis using value of information: a comparison of methods," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 383-392, April.
    8. Felipa, de Mello-Sampayo, 2014. "The Timing and Probability of Switching to Second-line Regimen - An application to Second-Line Antiretroviral Therapy in India," MPRA Paper 60997, University Library of Munich, Germany.

  3. McCabe, C & Brazier, J & Gilks, P & Tsuchiya, A & Roberts, J & O'Hagan, A & Stevens, K, 2004. "Estimating population cardinal health state valuation models from individual ordinal (rank) health state preference data," MPRA Paper 29759, University Library of Munich, Germany.

    Cited by:

    1. Brazier, J, 2005. "Current state of the art in preference-based measures of health and avenues for further research," MPRA Paper 29762, University Library of Munich, Germany.

  4. McCabe, C & Stevens, K & Roberts, J & Brazier, JE, 2003. "Health state values for the HUI 2 descriptive system: results from a UK survey," MPRA Paper 29744, University Library of Munich, Germany.

    Cited by:

    1. Donna Rowen & John Brazier & Aki Tsuchiya & Tracey Young & Rachel Ibbotson, 2012. "It’s All in the Name, or Is It? The Impact of Labeling on Health State Values," Medical Decision Making, , vol. 32(1), pages 31-40, January.
    2. Lidia Engel & Nick Bansback & Stirling Bryan & Mary M. Doyle-Waters & David G. T. Whitehurst, 2016. "Exclusion Criteria in National Health State Valuation Studies," Medical Decision Making, , vol. 36(7), pages 798-810, October.
    3. Musal, R. Muzaffer & Soyer, Refik & McCabe, Christopher & Kharroubi, Samer A., 2012. "Estimating the population utility function: A parametric Bayesian approach," European Journal of Operational Research, Elsevier, vol. 218(2), pages 538-547.
    4. Rowen, D & Brazier, J & Roberts, J, 2008. "Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?," MPRA Paper 29831, University Library of Munich, Germany.
    5. Mónica Hernández Alava & John Brazier & Donna Rowen & Aki Tsuchiya, 2013. "Common Scale Valuations across Different Preference-Based Measures," Medical Decision Making, , vol. 33(6), pages 839-852, August.
    6. Kim Dalziel & Max Catchpool & Borja García-Lorenzo & Inigo Gorostiza & Richard Norman & Oliver Rivero-Arias, 2020. "Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling," PharmacoEconomics, Springer, vol. 38(5), pages 499-513, May.
    7. Christopher McCabe & Richard Edlin & David Meads & Chantelle Brown & Samer Kharroubi, 2013. "Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities," PharmacoEconomics, Springer, vol. 31(8), pages 635-641, August.
    8. Katherine Stevens, 2012. "Valuation of the Child Health Utility 9D Index," PharmacoEconomics, Springer, vol. 30(8), pages 729-747, August.
    9. Samer A. Kharroubi & Yara Beyh & Esmail Abdul Fattah & Tracey Young, 2020. "The Importance of Accounting for Parameter Uncertainty in SF-6D Value Sets and Its Impact on Studies that Use the SF-6D to Measure Health Utility," IJERPH, MDPI, vol. 17(11), pages 1-12, June.
    10. Clara Mukuria & Donna Rowen & Sue Harnan & Andrew Rawdin & Ruth Wong & Roberta Ara & John Brazier, 2019. "An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values," Applied Health Economics and Health Policy, Springer, vol. 17(3), pages 295-313, June.
    11. Donna Rowen & Clara Mukuria & Philip A. Powell & Allan Wailoo, 2022. "Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults," PharmacoEconomics, Springer, vol. 40(5), pages 479-488, May.
    12. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    13. Joseph Kwon & Louise Freijser & Elisabeth Huynh & Martin Howell & Gang Chen & Kamran Khan & Shahd Daher & Nia Roberts & Conrad Harrison & Sarah Smith & Nancy Devlin & Kirsten Howard & Emily Lancsar & , 2022. "Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures," PharmacoEconomics, Springer, vol. 40(4), pages 379-431, April.
    14. Valentina Prevolnik Rupel & Marko Ogorevc, 2021. "EQ-5D-Y Value Set for Slovenia," PharmacoEconomics, Springer, vol. 39(4), pages 463-471, April.
    15. McCabe, C & Brazier, J & Gilks, P & Tsuchiya, A & Roberts, J & O'Hagan, A & Stevens, K, 2004. "Estimating population cardinal health state valuation models from individual ordinal (rank) health state preference data," MPRA Paper 29759, University Library of Munich, Germany.
    16. Cate Bailey & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Elisabeth Huynh & Emily Lancsar & Brendan J. Mulhern & Richard Nor, 2022. "Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review," PharmacoEconomics, Springer, vol. 40(7), pages 663-698, July.
    17. Piérard, Emmanuelle, 2014. "The effect of physician supply on health status: Canadian evidence," Health Policy, Elsevier, vol. 118(1), pages 56-65.
    18. Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe, 2020. "Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?," PharmacoEconomics, Springer, vol. 38(4), pages 325-340, April.
    19. Donna Rowen & John Brazier & Aki Tsuchiya & Mónica Hernández Alava, 2012. "Valuing states from multiple measures on the same visual analogue sale: a feasibility study," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 715-729, June.
    20. Brazier, John & Rowen, Donna & Tsuchiya, Aki & Yang, Yaling & Young, Tracy A., 2011. "The impact of adding an extra dimension to a preference-based measure," Social Science & Medicine, Elsevier, vol. 73(2), pages 245-253, July.

Articles

  1. Christopher McCabe & Richard Edlin & David Meads & Chantelle Brown & Samer Kharroubi, 2013. "Constructing Indirect Utility Models: Some Observations on the Principles and Practice of Mapping to Obtain Health State Utilities," PharmacoEconomics, Springer, vol. 31(8), pages 635-641, August.

    Cited by:

    1. Jeff Round & Annie Hawton, 2017. "Statistical Alchemy: Conceptual Validity and Mapping to Generate Health State Utility Values," PharmacoEconomics - Open, Springer, vol. 1(4), pages 233-239, December.

  2. Yemi Oluboyede & Sandy Tubeuf & Chris McCabe, 2013. "Measuring health outcomes of adolescents: report from a pilot study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 11-19, February.

    Cited by:

    1. Sandy Tubeuf & Eirini-Christina Saloniki & David Cottrell, 2019. "Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England," PharmacoEconomics, Springer, vol. 37(4), pages 513-530, April.

  3. Peter Hall & Christopher McCabe, 2013. "What Evidence Is There for the Reimbursement of Personalised Medicine?," PharmacoEconomics, Springer, vol. 31(3), pages 181-183, March.

    Cited by:

    1. Leopold, C. & Vogler, S. & Habl, C. & Mantel-Teeuwisse, A.K. & Espin, J., 2013. "Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab," Health Policy, Elsevier, vol. 113(3), pages 313-322.
    2. Gregory Katz & Olivier Romano & Cyril Foa & Anne-Lise Vataire & Jean-Victor Chantelard & Robert Hervé & Hugues Barletta & Axel Durieux & Jean-Pierre Martin & Rémy Salmon, 2015. "Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France," PLOS ONE, Public Library of Science, vol. 10(6), pages 1-15, June.
    3. Veronika Kalouguina & Joël Wagner, 2020. "Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review," JRFM, MDPI, vol. 13(11), pages 1-22, November.

  4. Musal, R. Muzaffer & Soyer, Refik & McCabe, Christopher & Kharroubi, Samer A., 2012. "Estimating the population utility function: A parametric Bayesian approach," European Journal of Operational Research, Elsevier, vol. 218(2), pages 538-547.

    Cited by:

    1. Bottomley, Paul A. & Doyle, John R., 2013. "Comparing the validity of numerical judgements elicited by direct rating and point allocation: Insights from objectively verifiable perceptual tasks," European Journal of Operational Research, Elsevier, vol. 228(1), pages 148-157.
    2. Brett Houlding & Frank P. A. Coolen & Donnacha Bolger, 2015. "A Conjugate Class of Utility Functions for Sequential Decision Problems," Risk Analysis, John Wiley & Sons, vol. 35(9), pages 1611-1622, September.
    3. Yuri S. Popkov & Yuri A. Dubnov & Alexey Yu. Popkov, 2016. "New Method of Randomized Forecasting Using Entropy-Robust Estimation: Application to the World Population Prediction," Mathematics, MDPI, vol. 4(1), pages 1-16, March.

  5. Stevens, Katherine & McCabe, Christopher & Brazier, John & Roberts, Jennifer, 2007. "Multi-attribute utility function or statistical inference models: A comparison of health state valuation models using the HUI2 health state classification system," Journal of Health Economics, Elsevier, vol. 26(5), pages 992-1002, September.

    Cited by:

    1. Anirban Basu & William Dale & Arthur Elstein & David Meltzer, 2009. "A linear index for predicting joint health‐states utilities from single health‐states utilities," Health Economics, John Wiley & Sons, Ltd., vol. 18(4), pages 403-419, April.
    2. John Brazier & Jennifer Roberts, 2006. "Methods for Developing Preference-based Measures of Health," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, chapter 35, Edward Elgar Publishing.
    3. Cathleen Johnson & Aurélien Baillon & Han Bleichrodt & Zhihua Li & Dennie Dolder & Peter P. Wakker, 2021. "Prince: An improved method for measuring incentivized preferences," Journal of Risk and Uncertainty, Springer, vol. 62(1), pages 1-28, February.
    4. George Tomlinson & Karen E. Bremner & Paul Ritvo & Gary Naglie & Murray D. Krahn, 2012. "Development and Validation of a Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS)," Medical Decision Making, , vol. 32(1), pages 11-30, January.
    5. Gang Chen & Julie Ratcliffe, 2015. "A Review of the Development and Application of Generic Multi-Attribute Utility Instruments for Paediatric Populations," PharmacoEconomics, Springer, vol. 33(10), pages 1013-1028, October.

  6. John Brazier & Christopher McCabe, 2007. "‘Is there a case for using visual analogue scale valuations in CUA’ by Parkin and Devlin a response: ‘yes there is a case, but what does it add to ordinal data?’," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 645-647, June.

    Cited by:

    1. Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés, 2013. "Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 33-42, July.
    2. Nancy J. Devlin & Koonal K. Shah & Brendan J. Mulhern & Krystallia Pantiri & Ben van Hout, 2019. "A new method for valuing health: directly eliciting personal utility functions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 257-270, March.
    3. Edward J. D. Webb & John O’Dwyer & David Meads & Paul Kind & Penny Wright, 2020. "Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 787-800, July.

  7. McCabe, Christopher & Brazier, John & Gilks, Peter & Tsuchiya, Aki & Roberts, Jennifer & O'Hagan, Anthony & Stevens, Katherine, 2006. "Using rank data to estimate health state utility models," Journal of Health Economics, Elsevier, vol. 25(3), pages 418-431, May.

    Cited by:

    1. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2012. "Using a discrete choice experiment to estimate health state utility values," Journal of Health Economics, Elsevier, vol. 31(1), pages 306-318.
    2. Luciana Scalone & Peep Stalmeier & Silvano Milani & Paul Krabbe, 2015. "Values for health states with different life durations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 917-925, December.
    3. John Brazier & Christopher McCabe, 2007. "‘Is there a case for using visual analogue scale valuations in CUA’ by Parkin and Devlin a response: ‘yes there is a case, but what does it add to ordinal data?’," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 645-647, June.
    4. Päivi Kolu & Jani Raitanen & Clas-Håkan Nygård & Eija Tomás & Riitta Luoto, 2015. "Cost-Effectiveness of Physical Activity among Women with Menopause Symptoms: Findings from a Randomised Controlled Trial," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-14, August.
    5. Hareth Al-Janabi & Terry N. Flynn & Joanna Coast, 2011. "Estimation of a Preference-Based Carer Experience Scale," Medical Decision Making, , vol. 31(3), pages 458-468, May.
    6. Paul F. M. Krabbe & Elly A. Stolk & Nancy J. Devlin & Feng Xie & Elise H. Quik & A. Simon Pickard, 2017. "Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(8), pages 967-977, November.
    7. Mónica Hernández Alava & John Brazier & Donna Rowen & Aki Tsuchiya, 2013. "Common Scale Valuations across Different Preference-Based Measures," Medical Decision Making, , vol. 33(6), pages 839-852, August.
    8. John Brazier & Donna Rowen & Yaling Yang & Aki Tsuchiya, 2012. "Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 575-587, October.
    9. Julie Ratcliffe & John Brazier & Aki Tsuchiya & Tara Symonds & Martin Brown, 2009. "Using DCE and ranking data to estimate cardinal values for health states for deriving a preference‐based single index from the sexual quality of life questionnaire," Health Economics, John Wiley & Sons, Ltd., vol. 18(11), pages 1261-1276, November.
    10. Juan Ramos-Goñi & Oliver Rivero-Arias & María Errea & Elly Stolk & Michael Herdman & Juan Cabasés, 2013. "Dealing with the health state ‘dead’ when using discrete choice experiments to obtain values for EQ-5D-5L heath states," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 33-42, July.
    11. Paul F M Krabbe & Ruslan Jabrayilov & Patrick Detzel & Livia Dainelli & Karin M Vermeulen & Antoinette D I van Asselt, 2020. "A two-step procedure to generate utilities for the Infant health-related Quality of life Instrument (IQI)," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-14, April.
    12. Julie Ratcliffe & Leah Couzner & Terry Flynn & Michael Sawyer & Katherine Stevens & John Brazier & Leonie Burgess, 2011. "Valuing child health utility 9D health states with a young adolescent sample," Applied Health Economics and Health Policy, Springer, vol. 9(1), pages 15-27, January.
    13. Rosalie Viney & Richard Norman & John Brazier & Paula Cronin & Madeleine T. King & Julie Ratcliffe & Deborah Street, 2014. "An Australian Discrete Choice Experiment To Value Eq‐5d Health States," Health Economics, John Wiley & Sons, Ltd., vol. 23(6), pages 729-742, June.
    14. Stevens, K, 2010. "Valuation of the Child Health Utility Index 9D (CHU9D)," MPRA Paper 29938, University Library of Munich, Germany.
    15. Yan, Jin & Yoo, Hong Il, 2019. "Semiparametric estimation of the random utility model with rank-ordered choice data," Journal of Econometrics, Elsevier, vol. 211(2), pages 414-438.
    16. Bansback, Nick & Brazier, John & Tsuchiya, Aki & Anis, Aslam, 2010. "Using a discrete choice experiment to estimate societal health state utility values," MPRA Paper 29933, University Library of Munich, Germany.
    17. Katherine Stevens, 2012. "Valuation of the Child Health Utility 9D Index," PharmacoEconomics, Springer, vol. 30(8), pages 729-747, August.
    18. Paul F M Krabbe, 2013. "A Generalized Measurement Model to Quantify Health: The Multi-Attribute Preference Response Model," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-12, November.
    19. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    20. Brazier, J & Rowen, D & Yang, Y & Tsuchiya, A, 2009. "Using rank and discrete choice data to estimate health state utility values on the QALY scale," MPRA Paper 29891, University Library of Munich, Germany.
    21. Ratcliffe, J & Brazier, J & Tsuchiya, A & Symonds, T & Brown, M, 2006. "Estimation of a preference based single index from the sexual quality of life questionnaire (SQOL) using ordinal data," MPRA Paper 29768, University Library of Munich, Germany.
    22. Adedokun Oluwafemi Ojelabi & Afolabi Elijah Bamgboye & Jonathan Ling, 2019. "Preference-based measure of health-related quality of life and its determinants in sickle cell disease in Nigeria," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-16, November.
    23. Nicolas A. Menzies & Joshua A. Salomon, 2011. "Non‐monotonicity in the episodic random utility model," Health Economics, John Wiley & Sons, Ltd., vol. 20(12), pages 1523-1531, December.
    24. Terry N. Flynn & Elisabeth Huynh & Tim J. Peters & Hareth Al‐Janabi & Sam Clemens & Alison Moody & Joanna Coast, 2015. "Scoring the Icecap‐a Capability Instrument. Estimation of a UK General Population Tariff," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 258-269, March.
    25. Feng Xie & Eleanor Pullenayegum & A. Simon Pickard & Juan Manuel Ramos Goñi & Min‐woo Jo & Ataru Igarashi, 2017. "Transforming Latent Utilities to Health Utilities: East Does Not Meet West," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1524-1533, December.
    26. Mina Bahrampour & Joshua Byrnes & Richard Norman & Paul A. Scuffham & Martin Downes, 2020. "Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 983-992, September.
    27. Osman, Ahmed M.Y. & Wu, Jing & He, Xiaoning & Chen, Gang, 2021. "Eliciting SF-6Dv2 health state utilities using an anchored best-worst scaling technique," Social Science & Medicine, Elsevier, vol. 279(C).
    28. Terry Flynn, 2010. "Using Conjoint Analysis and Choice Experiments to Estimate QALY Values," PharmacoEconomics, Springer, vol. 28(9), pages 711-722, September.

  8. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.

    Cited by:

    1. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
    2. Schulenburg J.-Matthias Graf von der & Vauth Christoph, 2007. "Nach welchen ökonomischen Methoden sollten Gesundheitsleistungen in Deutschland evaluiert werden? / According to Which Economic Methods Should Health Care Services Become Evaluated in Germany?," Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 227(5-6), pages 787-806, October.
    3. Manca, A & Austin, P. C, 2008. "Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies," Health, Econometrics and Data Group (HEDG) Working Papers 08/20, HEDG, c/o Department of Economics, University of York.
    4. Ulla Griffiths & Benedict Anigbogu & Kiran Nanchahal, 2012. "Economic evaluations of adult weight management interventions," Applied Health Economics and Health Policy, Springer, vol. 10(3), pages 145-162, May.
    5. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Management of Dementia Patients - A Systematic Literature Review," Working Papers 2018:41, Lund University, Department of Economics.
    6. Graves, Nicholas & Clare, Gina & Haines, Mary & Bird, Robert, 2010. "A policy case study of blood in Australia," Social Science & Medicine, Elsevier, vol. 71(9), pages 1677-1682, November.
    7. Sean Docking & Lan Gao & Zanfina Ademi & Christian Bonello & Rachelle Buchbinder, 2023. "Use of Decision-Analytic Modelling to Assess the Cost-Effectiveness of Diagnostic Imaging of the Spine, Shoulder, and Knee: A Scoping Review," Applied Health Economics and Health Policy, Springer, vol. 21(3), pages 467-475, May.
    8. John W. Stevens, 2018. "Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?," PharmacoEconomics, Springer, vol. 36(10), pages 1135-1141, October.
    9. Dina Jankovic & Laura Bojke & David Marshall & Pedro Saramago Goncalves & Rachel Churchill & Hollie Melton & Sally Brabyn & Lina Gega, 2021. "Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions," Applied Health Economics and Health Policy, Springer, vol. 19(1), pages 17-27, January.
    10. Edward Burn & Alexander D. Liddle & Thomas W. Hamilton & Sunil Pai & Hemant G. Pandit & David W. Murray & Rafael Pinedo-Villanueva, 2017. "Choosing Between Unicompartmental and Total Knee Replacement: What Can Economic Evaluations Tell Us? A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(4), pages 241-253, December.
    11. Renee Lévesque & Daniele Marcelli & Héloïse Cardinal & Marie-Line Caron & Muriel Grooteman & Michiel Bots & Peter Blankestijn & Menso Nubé & Aileen Grassmann & Bernard Canaud & Afschin Gandjour, 2015. "Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 647-659, December.
    12. Marta O. Soares & Simon Walker & Stephen J. Palmer & Mark J. Sculpher, 2018. "Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment," Medical Decision Making, , vol. 38(4), pages 495-508, May.
    13. Daisuke Goto & Ya-Chen Tina Shih & Pascal Lecomte & Melvin Olson & Chukwukadibia Udeze & Yujin Park & C. Daniel Mullins, 2017. "Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(7), pages 685-695, July.
    14. Kerry Bell & Belen Corbacho & Sarah Ronaldson & Gerry Richardson & David Torgerson & Michael Robling, 2018. "The impact of pre and perinatal lifestyle factors on child long term health and social outcomes: a systematic review," Health Economics Review, Springer, vol. 8(1), pages 1-18, December.
    15. Alexander Thompson & Bruce Guthrie & Katherine Payne, 2016. "Do Pills Have No Ills? Capturing the Impact of Direct Treatment Disutility," PharmacoEconomics, Springer, vol. 34(4), pages 333-336, April.
    16. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    17. Mohsen Ghaffari Darab & Lidia Engel & Dennis Henzler & Michael Lauerer & Eckhard Nagel & Vicki Brown & Cathrine Mihalopoulos, 2024. "Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 503-525, July.
    18. Lois G. Kim & Simon G. Thompson, 2010. "Uncertainty and validation of health economic decision models," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 43-55, January.
    19. Ulla Kou Griffiths & Rosa Legood & Catherine Pitt, 2016. "Comparison of Economic Evaluation Methods Across Low‐income, Middle‐income and High‐income Countries: What are the Differences and Why?," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 29-41, February.
    20. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
    21. Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.
    22. James A. Hall & Kika Konstantinou & Martyn Lewis & Raymond Oppong & Reuben Ogollah & Sue Jowett, 2019. "Systematic Review of Decision Analytic Modelling in Economic Evaluations of Low Back Pain and Sciatica," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 467-491, August.
    23. Takahashi, R. & Todo, Y., 2018. "When do consumers stand up for the environment? Evidence from a large-scale social experiment to promote environmentally friendly coffee," 2018 Conference, July 28-August 2, 2018, Vancouver, British Columbia 277507, International Association of Agricultural Economists.
    24. J. Caro & Jörgen Möller, 2014. "Decision-Analytic Models: Current Methodological Challenges," PharmacoEconomics, Springer, vol. 32(10), pages 943-950, October.
    25. Sanjib Saha & Katarina Steen Carlsson & Ulf-G Gerdtham & Margareta K Eriksson & Lars Hagberg & Mats Eliasson & Pia Johansson, 2013. "Are Lifestyle Interventions in Primary Care Cost-Effective? – An Analysis Based on a Markov Model, Differences-In-Differences Approach and the Swedish Björknäs Study," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-1, November.
    26. Brousselle, Astrid & Lessard, Chantale, 2011. "Economic evaluation to inform health care decision-making: Promise, pitfalls and a proposal for an alternative path," Social Science & Medicine, Elsevier, vol. 72(6), pages 832-839, March.
    27. Dixon, Padraig & Harrison, Sean & Hollingworth, William & Davies, Neil M. & Davey Smith, George, 2022. "Estimating the causal effect of liability to disease on healthcare costs using Mendelian Randomization," Economics & Human Biology, Elsevier, vol. 46(C).
    28. David Glynn & John Giardina & Julia Hatamyar & Ankur Pandya & Marta Soares & Noemi Kreif, 2024. "Integrating decision modeling and machine learning to inform treatment stratification," Health Economics, John Wiley & Sons, Ltd., vol. 33(8), pages 1772-1792, August.
    29. Gemma E. Shields & Becky Pennington & Ash Bullement & Stuart Wright & Jamie Elvidge, 2022. "Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time," PharmacoEconomics, Springer, vol. 40(3), pages 249-256, March.
    30. Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi, 2014. "Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes," PharmacoEconomics, Springer, vol. 32(10), pages 995-1004, October.
    31. Edward Wilson, 2015. "A Practical Guide to Value of Information Analysis," PharmacoEconomics, Springer, vol. 33(2), pages 105-121, February.
    32. Ana Sofia Oliveira Gonçalves & Dimitra Panteli & Lars Neeb & Tobias Kurth & Annette Aigner, 2022. "HIT-6 and EQ-5D-5L in patients with migraine: assessment of common latent constructs and development of a mapping algorithm," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(1), pages 47-57, February.
    33. Stavros Petrou & Joseph Kwon & Jason Madan, 2018. "A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values," PharmacoEconomics, Springer, vol. 36(9), pages 1043-1061, September.
    34. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2020. "Modelling the impact of physical activity on public health: A review and critique," Health Policy, Elsevier, vol. 124(10), pages 1155-1164.
    35. Andrew Briggs, 2012. "Statistical Methods for Cost-effectiveness Analysis Alongside Clinical Trials," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 50, Edward Elgar Publishing.
    36. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
    37. Christoffer Lilja Terjesen & Julia Kovaleva & Lars Ehlers, 2017. "Early Assessment of the Likely Cost Effectiveness of Single-Use Flexible Video Bronchoscopes," PharmacoEconomics - Open, Springer, vol. 1(2), pages 133-141, June.
    38. Stuart J. Wright & Ewan Gray & Gabriel Rogers & Anna Donten & Katherine Payne, 2024. "A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 527-542, July.
    39. J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner, 2007. "Methods for determining cost-benefit ratios for pharmaceuticals in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 5-31, September.
    40. Ferrari, Giulia & Torres-Rueda, Sergio & Michaels-Igbokwe, Christine & Watts, Charlotte & Jewkes, Rachel & Vassall, Anna, 2019. "Economic evaluation of public health interventions: an application to interventions for the prevention of violence against women and girls implemented by the “what works to prevent violence against wo," LSE Research Online Documents on Economics 103639, London School of Economics and Political Science, LSE Library.
    41. Cynthia P. Iglesias & Alexander Thompson & Wolf H. Rogowski & Katherine Payne, 2016. "Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations," PharmacoEconomics, Springer, vol. 34(11), pages 1161-1172, November.
    42. Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
    43. Rob Anderson, 2010. "Systematic reviews of economic evaluations: utility or futility?," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 350-364, March.
    44. Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast, 2017. "How Qualitative Methods Can be Used to Inform Model Development," PharmacoEconomics, Springer, vol. 35(6), pages 607-612, June.

  9. Christopher McCabe & Katherine Stevens & Jennifer Roberts & John Brazier, 2006. "Erratum to ‘Health state values for the health utilities index mark 2 descriptive system: results from a UK valuation survey’ Health Economics 2005; 14(3): 231–244," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 761-761, July.

    Cited by:

    1. Stevens, K, 2010. "Valuation of the Child Health Utility Index 9D (CHU9D)," MPRA Paper 29938, University Library of Munich, Germany.

  10. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4, January.

    Cited by:

    1. van Baal, P.H. & Feenstra, T.L. & Polder, J.J. & Hoogenveen, R.T. & Brouwer, W., 2011. "Economic evaluation and the postponement of health care costs," Other publications TiSEM ee3d1a20-234a-46d7-8acd-d, Tilburg University, School of Economics and Management.
    2. M. Parouty & H. Le & D. Krooshof & M. Postma, 2014. "Differential Time Preferences for Money and Quality of Life," PharmacoEconomics, Springer, vol. 32(4), pages 411-419, April.
    3. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    4. van der Pol, Marjon & Cairns, John, 2008. "Comparison of two methods of eliciting time preference for future health states," Social Science & Medicine, Elsevier, vol. 67(5), pages 883-889, September.
    5. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    6. Paul Hanly & Michelle Ahern & Linda Sharp & Diana Ursul & Gerard Loughnane, 2022. "The cost of lost productivity due to premature mortality associated with COVID-19: a Pan-European study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 249-259, March.
    7. Mike Paulden & Anthony J Culyer, 2010. "Does cost-effectiveness analysis discriminate against patients with short life expectancy? Matters of logic and matters of context," Working Papers 055cherp, Centre for Health Economics, University of York.
    8. Mike Paulden & James F. O’Mahony & Christopher McCabe, 2017. "Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine," PharmacoEconomics, Springer, vol. 35(1), pages 5-13, January.
    9. Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe, 2014. "Some Inconsistencies in NICE’s Consideration of Social Values," PharmacoEconomics, Springer, vol. 32(11), pages 1043-1053, November.
    10. Hugh Gravelle & Werner Brouwer & Louis Niessen & Maarten Postma & Frans Rutten, 2007. "Discounting in economic evaluations: stepping forward towards optimal decision rules," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 307-317, March.
    11. Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton, 2018. "Discounting in Economic Evaluations," PharmacoEconomics, Springer, vol. 36(7), pages 745-758, July.
    12. Erik Nord, 2011. "Discounting future health benefits: the poverty of consistency arguments," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 16-26, January.
    13. Karl Claxton & Mike Paulden & Hugh Gravelle & Werner Brouwer & Anthony J. Culyer, 2011. "Discounting and decision making in the economic evaluation of health‐care technologies," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 2-15, January.
    14. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
    15. Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
    16. Mike Paulden & Anthony J. Culyer, 2010. "Does Cost-Effectiveness Analysis Discriminate against Patients with Short Life Expectancy?," Working Paper series 41_10, Rimini Centre for Economic Analysis.
    17. Mareike Schad & Jürgen John, 2012. "Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 127-144, April.
    18. Ana Bobinac & Werner Brouwer & Job van Exel, 2011. "Discounting future health gains: an empirical enquiry into the influence of growing life expectancy," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 111-119, January.

  11. Katherine J. Stevens & Christopher J. McCabe & John E. Brazier, 2006. "Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey," Health Economics, John Wiley & Sons, Ltd., vol. 15(5), pages 527-533, May.

    Cited by:

    1. Costa-Font, Montserrat & Costa-Font, Joan, 2009. "Heterogeneous 'adaptation' and 'income effects' across self-reported health distribution?," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 38(4), pages 574-580, August.
    2. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    3. Donna Rowen & John Brazier & Aki Tsuchiya & Mónica Hernández Alava, 2012. "Valuing states from multiple measures on the same visual analogue sale: a feasibility study," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 715-729, June.
    4. Katherine Stevens & Christopher McCabe & John Brazier, 2007. "Response to Shmueli," Health Economics, John Wiley & Sons, Ltd., vol. 16(7), pages 759-761, July.

  12. Christopher McCabe & Katherine Stevens & Jennifer Roberts & John Brazier, 2005. "Health state values for the HUI 2 descriptive system: results from a UK survey," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 231-244, March.
    See citations under working paper version above.
  13. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347, April.

    Cited by:

    1. Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher, 2006. "Defining and characterising structural uncertainty in decision analytic models," Working Papers 009cherp, Centre for Health Economics, University of York.
    2. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
    3. Anthony J. Hatswell & Ash Bullement & Andrew Briggs & Mike Paulden & Matthew D. Stevenson, 2018. "Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models," PharmacoEconomics, Springer, vol. 36(12), pages 1421-1426, December.
    4. John W. Stevens, 2018. "Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?," PharmacoEconomics, Springer, vol. 36(10), pages 1135-1141, October.
    5. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2017. "A Review of Methods for Analysis of the Expected Value of Information," Medical Decision Making, , vol. 37(7), pages 747-758, October.
    6. Lionel Perrier & Anne Lefranc & Philippe Quittet & Philippe Moreau & Carole Siani & Hervé Ghesquières & Fabrice Jardin & Bertrand Favier & Norbert Ifrah & Séverine Lissandre & David Pérol & Catherine , 2013. "Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma," Post-Print halshs-00752571, HAL.
    7. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    8. Dominic Tilden & Segundo Mariz & Gillies O’Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos, 2007. "A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK," PharmacoEconomics, Springer, vol. 25(1), pages 39-54, January.
    9. Anna Heath & Ioanna Manolopoulou & Gianluca Baio, 2019. "Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression," Medical Decision Making, , vol. 39(4), pages 347-359, May.
    10. Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi, 2019. "Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review," PharmacoEconomics, Springer, vol. 37(6), pages 777-818, June.
    11. Michelle Tew & Michael Willis & Christian Asseburg & Hayley Bennett & Alan Brennan & Talitha Feenstra & James Gahn & Alastair Gray & Laura Heathcote & William H. Herman & Deanna Isaman & Shihchen Kuo , 2022. "Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Chal," Medical Decision Making, , vol. 42(5), pages 599-611, July.
    12. Pedram Sendi & Huldrych F Günthard & Mathew Simcock & Bruno Ledergerber & Jörg Schüpbach & Manuel Battegay & for the Swiss HIV Cohort Study, 2007. "Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure," PLOS ONE, Public Library of Science, vol. 2(1), pages 1-8, January.
    13. Christopher McCabe & Mike Paulden & Isaac Awotwe & Andrew Sutton & Peter Hall, 2020. "One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit," PharmacoEconomics, Springer, vol. 38(2), pages 135-141, February.
    14. Isaac Corro Ramos & Maureen P. M. H. Rutten-van Mölken & Maiwenn J. Al, 2013. "The Role of Value-of-Information Analysis in a Health Care Research Priority Setting," Medical Decision Making, , vol. 33(4), pages 472-489, May.
    15. Mohan V. Bala & Gary A. Zarkin & Josephine Mauskopf, 2008. "Presenting results of probabilistic sensitivity analysis: the incremental benefit curve," Health Economics, John Wiley & Sons, Ltd., vol. 17(3), pages 435-440, March.
    16. Anthony O'Hagan & Matt Stevenson & Jason Madan, 2007. "Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA," Health Economics, John Wiley & Sons, Ltd., vol. 16(10), pages 1009-1023, October.
    17. Sun-Young Kim & Louise B. Russell & Anushua Sinha, 2015. "Handling Parameter Uncertainty in Cost-Effectiveness Models Simply and Responsibly," Medical Decision Making, , vol. 35(5), pages 567-569, July.
    18. James Love-Koh & Susan Griffin & Edward Kataika & Paul Revill & Sibusiso Sibandze & Simon Walker & Jessica Ochalek & Mark Sculpher & Matthias Arnold, 2019. "Economic analysis for health benefits package design," Working Papers 165cherp, Centre for Health Economics, University of York.
    19. Mark Sculpher & Stephen Palmer, 2020. "After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?," PharmacoEconomics, Springer, vol. 38(3), pages 247-257, March.
    20. Adam J. N. Raymakers & John Mayo & Stephen Lam & J. Mark FitzGerald & David G. T. Whitehurst & Larry D. Lynd, 2016. "Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 409-418, August.
    21. T. I. Armina Padmasawitri & Sarah Maria Saragih & Gerardus W. Frederix & Olaf Klungel & Anke M. Hövels, 2020. "Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 4(2), pages 223-233, June.
    22. Bogdan Grigore & Oriana Ciani & Florian Dams & Carlo Federici & Saskia Groot & Meilin Möllenkamp & Stefan Rabbe & Kosta Shatrov & Antal Zemplenyi & Rod S. Taylor, 2020. "Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines," PharmacoEconomics, Springer, vol. 38(10), pages 1055-1070, October.
    23. Zoë Pieters & Mark Strong & Virginia E. Pitzer & Philippe Beutels & Joke Bilcke, 2020. "A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations," Medical Decision Making, , vol. 40(5), pages 669-679, July.
    24. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
    25. Mehdi Najafzadeh & Jorge A. Garces & Alejandra Maciel, 2017. "Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety," PharmacoEconomics, Springer, vol. 35(12), pages 1297-1310, December.
    26. Kurinchi Gurusamy & Edward Wilson & Andrew Burroughs & Brian Davidson, 2012. "Intra-operative vs pre-operative endoscopic sphincterotomy in patients with gallbladder and common bile duct stones," Applied Health Economics and Health Policy, Springer, vol. 10(1), pages 15-29, January.
    27. Nicky J. Welton & Jason J. Madan & Deborah M. Caldwell & Tim J. Peters & Anthony E. Ades, 2014. "Expected Value of Sample Information for Multi-Arm Cluster Randomized Trials with Binary Outcomes," Medical Decision Making, , vol. 34(3), pages 352-365, April.
    28. Xuanqian Xie & Alexis K. Schaink & Sichen Liu & Myra Wang & Andrei Volodin, 2023. "Understanding bias in probabilistic analysis in model-based health economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 307-319, March.
    29. Samer A. Kharroubi & Richard Edlin & David Meads & Chantelle Browne & Julia Brown & Christopher McCabe, 2015. "Use of Bayesian Markov Chain Monte Carlo Methods to Estimate EQ-5D Utility Scores from EORTC QLQ Data in Myeloma for Use in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 35(3), pages 351-360, April.
    30. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial‐based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687, July.
    31. Benjamin Thorpe & Orlagh Carroll & Linda Sharples, 2018. "Methods for Handling Unobserved Covariates in a Bayesian Update of a Cost-effectiveness Model," Medical Decision Making, , vol. 38(2), pages 150-162, February.
    32. Belfiore, Alessandra & Scaletti, Alessandro & Lavorato, Domenica & Cuccurullo, Corrado, 2023. "The long process by which HTA became a paradigm: A longitudinal conceptual structure analysis," Health Policy, Elsevier, vol. 127(C), pages 74-79.
    33. Devin Incerti & Jeffrey R. Curtis & Jason Shafrin & Darius N. Lakdawalla & Jeroen P. Jansen, 2019. "A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis," PharmacoEconomics, Springer, vol. 37(6), pages 829-843, June.
    34. Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen, 2014. "Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010," PharmacoEconomics, Springer, vol. 32(4), pages 367-375, April.
    35. Laura Bojke & Marta O. Soares & Karl Claxton & Abigail Colson & Aimée Fox & Chris Jackson & Dina Jankovic & Alec Morton & Linda D. Sharples & Andrea Taylor, 2022. "Reference Case Methods for Expert Elicitation in Health Care Decision Making," Medical Decision Making, , vol. 42(2), pages 182-193, February.
    36. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    37. Mattias Ekman & Peter Lindgren & Carolin Miltenburger & Genevieve Meier & Julie Locklear & Mary Chatterton, 2012. "Cost Effectiveness of Quetiapine in Patients with Acute Bipolar Depression and in Maintenance Treatment after an Acute Depressive Episode," PharmacoEconomics, Springer, vol. 30(6), pages 513-530, June.
    38. Bogdan Grigore & Jaime Peters & Christopher Hyde & Ken Stein, 2013. "Methods to Elicit Probability Distributions from Experts: A Systematic Review of Reported Practice in Health Technology Assessment," PharmacoEconomics, Springer, vol. 31(11), pages 991-1003, November.
    39. Anna Heath & Mark Strong & David Glynn & Natalia Kunst & Nicky J. Welton & Jeremy D. Goldhaber-Fiebert, 2022. "Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial," Medical Decision Making, , vol. 42(2), pages 143-155, February.
    40. Sofia Dias & Alex J. Sutton & A. E. Ades & Nicky J. Welton, 2013. "Evidence Synthesis for Decision Making 2," Medical Decision Making, , vol. 33(5), pages 607-617, July.
    41. White, Nicole & Blythe, Robin, 2023. "ShinyPrior: A tool for estimating probability distributions using published evidence," OSF Preprints zf62e, Center for Open Science.
    42. Matt Stevenson & Peter Selby, 2014. "Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider," PharmacoEconomics, Springer, vol. 32(8), pages 735-743, August.
    43. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
    44. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    45. Peter J. Dodd & Debebe Shaweno & Chu-Chang Ku & Philippe Glaziou & Carel Pretorius & Richard J. Hayes & Peter MacPherson & Ted Cohen & Helen Ayles, 2023. "Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    46. Ji-Hee Youn & Matt D. Stevenson & Praveen Thokala & Katherine Payne & Maria Goddard, 2019. "Modeling the Economic Impact of Interventions for Older Populations with Multimorbidity: A Method of Linking Multiple Single-Disease Models," Medical Decision Making, , vol. 39(7), pages 842-856, October.
    47. Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume, 2006. "Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 137-144, June.
    48. Anthony Newall & Mark Jit & Philippe Beutels, 2012. "Economic Evaluations of Childhood Influenza Vaccination," PharmacoEconomics, Springer, vol. 30(8), pages 647-660, August.
    49. Christopher McCabe & Giovanni Tramonti & Andrew Sutton & Peter Hall & Mike Paulden, 2021. "Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier," PharmacoEconomics, Springer, vol. 39(1), pages 19-24, January.
    50. Pepijn Vemer & Lucas M. A. Goossens & Maureen P. M. H. Rutten-van Mölken, 2014. "Not Simply More of the Same," Medical Decision Making, , vol. 34(8), pages 1048-1058, November.
    51. Nicholas Graves & Katie Page & Elizabeth Martin & David Brain & Lisa Hall & Megan Campbell & Naomi Fulop & Nerina Jimmeison & Katherine White & David Paterson & Adrian G Barnett, 2016. "Cost-Effectiveness of a National Initiative to Improve Hand Hygiene Compliance Using the Outcome of Healthcare Associated Staphylococcus aureus Bacteraemia," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-17, February.
    52. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
    53. Emma McIntosh, 2006. "Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework," PharmacoEconomics, Springer, vol. 24(9), pages 855-868, September.
    54. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
    55. Tiago M. de Carvalho & Eveline A. M. Heijnsdijk & Luc Coffeng & Harry J. de Koning, 2019. "Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators," Medical Decision Making, , vol. 39(4), pages 405-413, May.
    56. Yevgeniy Samyshkin & Robert Kotchie & Ann-Christin Mörk & Andrew Briggs & Eric Bateman, 2014. "Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 69-82, January.
    57. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    58. Anna Heath & Petros Pechlivanoglou, 2022. "Prioritizing Research in an Era of Personalized Medicine: The Potential Value of Unexplained Heterogeneity," Medical Decision Making, , vol. 42(5), pages 649-660, July.
    59. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
    60. Shijie Ren & Jonathan Minton & Sophie Whyte & Nicholas R. Latimer & Matt Stevenson, 2018. "A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis," PharmacoEconomics, Springer, vol. 36(3), pages 341-347, March.
    61. Laura Bojke & Bogdan Grigore & Dina Jankovic & Jaime Peters & Marta Soares & Ken Stein, 2017. "Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties," PharmacoEconomics, Springer, vol. 35(9), pages 867-877, September.
    62. Christopher H. Jackson & Laura Bojke & Simon G. Thompson & Karl Claxton & Linda D. Sharples, 2011. "A Framework for Addressing Structural Uncertainty in Decision Models," Medical Decision Making, , vol. 31(4), pages 662-674, July.
    63. Daniel Hill-McManus, 2024. "The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations," PharmacoEconomics, Springer, vol. 42(1), pages 11-18, January.
    64. Helen A. Dakin & José Leal & Andrew Briggs & Philip Clarke & Rury R. Holman & Alastair Gray, 2020. "Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data," Medical Decision Making, , vol. 40(4), pages 460-473, May.
    65. Steven Edwards & Sarah Wordsworth & Mike Clarke, 2012. "Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 181-192, April.
    66. Karl Claxton & Stephen Palmer & Louise Longworth & Laura Bojke & Susan Griffin & Claire McKenna & Marta Soares & Eldon Spackman & Jihee Youn, 2011. "Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies," Working Papers 069cherp, Centre for Health Economics, University of York.
    67. Jagpreet Chhatwal & Tianhua He, 2015. "Economic Evaluations with Agent-Based Modelling: An Introduction," PharmacoEconomics, Springer, vol. 33(5), pages 423-433, May.
    68. Sofia Dias & Alex J. Sutton & Nicky J. Welton & A. E. Ades, 2013. "Evidence Synthesis for Decision Making 6," Medical Decision Making, , vol. 33(5), pages 671-678, July.
    69. Joseph F. Levy & Patrick D. Meek & Marjorie A. Rosenberg, 2015. "US-Based Drug Cost Parameter Estimation for Economic Evaluations," Medical Decision Making, , vol. 35(5), pages 622-632, July.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.